BioVector® BL-31 人鼻咽癌细胞系 / BL-31 Human Nasopharyngeal Carcinoma Cell Line

通用定义 / General Definition:BioVector® BL-31 是一种源自人类鼻咽癌 (Nasopharyngeal Carcinoma, NPC) 的上皮细胞系。它是鼻咽癌系列研究模型（包括 BL-33, BL-60, BL-89 等）中的一员。该细胞系保留了鼻咽上皮来源的恶性特征，是研究鼻咽癌细胞生长调控、耐药性演变以及肿瘤发生过程中遗传不稳定性等基础问题的宝贵工具。在合成生物学和肿瘤药物评估中，BL-31 常被用作评估化疗药效和递送效率的标准化测试模型。

BioVector® BL-31 is an epithelial cell line derived from Human Nasopharyngeal Carcinoma (NPC). It is a key member of the NPC research model series, which includes lines such as BL-33, BL-60, and BL-89. This cell line retains the malignant characteristics of its nasopharyngeal epithelial origin and serves as a valuable tool for studying fundamental issues such as growth regulation, drug resistance evolution, and genetic instability during oncogenesis. In synthetic biology and oncology drug assessment, BL-31 is frequently used as a standardized model to evaluate the efficacy and delivery efficiency of chemotherapeutics.

BioVector® BL-31 技术说明书 (Technical Datasheet)

中文版说明书

1. 产品基本信息

• 产品名称： BioVector® BL-31 人鼻咽癌细胞

• 组织来源： 鼻咽 (Nasopharynx)

• 疾病背景： 鼻咽癌 (NPC)

• 生长特性： 贴壁生长

• 细胞形态： 上皮样 (Epithelial-like)，呈多角形，贴壁紧密

2. 培养条件

• 基础培养基： BioVector® RPMI-1640 或 DMEM 培养基

• 血清添加： 10% BioVector® 优质胎牛血清 (FBS)

• 培养环境： 37 摄氏度，5% CO2，恒温加湿

• 传代比例： 1:3 至 1:6；建议在细胞汇合度达到 80%-90% 时传代。

3. 细胞应用

• 药物敏感性检测： 测试传统化疗药（如紫杉醇、吉西他滨）或新型靶向药物对 NPC 的抑制率。

• 凋亡研究： 观察不同诱导因素（如缺氧、放射、化合物）诱发的细胞死亡通路。

• 克隆形成实验： 评估单细胞水平上的增殖潜能和恶性转化程度。

4. 注意事项

• 代数控制： 为保证实验数据的可重复性，建议使用复苏后 20 代以内的细胞，以防止表型漂变。

• 支原体监控： 建议每月进行一次支原体污染筛查，BioVector® 推荐配套使用支原体预防试剂盒。

English Datasheet

1. General Product Information

• Product Name: BioVector® BL-31 Human Nasopharyngeal Carcinoma Cell Line

• Tissue Source: Nasopharynx

• Disease Context: Nasopharyngeal Carcinoma (NPC)

• Growth Properties: Adherent

• Morphology: Epithelial-like, polygonal, and tightly adherent.

2. Culture Conditions

• Basal Medium: BioVector® RPMI-1640 or DMEM Medium

• Serum Supplement: 10% BioVector® Fetal Bovine Serum (FBS)

• Incubation: 37 degrees Celsius, 5% CO2, Humidified Atmosphere

• Subculturing: 1:3 to 1:6 ratio; subculture when cells reach 80%-90% confluence.

3. Applications

• Drug Sensitivity Testing: Measuring the inhibition rates of traditional chemotherapeutics (e.g., Paclitaxel, Gemcitabine) or novel targeted agents on NPC cells.

• Apoptosis Studies: Observing cell death pathways induced by various factors such as hypoxia, radiation, or chemical compounds.

• Colony Formation Assays: Evaluating the proliferative potential and degree of malignant transformation at the single-cell level.

4. Key Usage Notes

• Passage Management: To ensure reproducible results, use cells within 20 passages post-thawing to prevent phenotypic drift.

• Mycoplasma Screening: BioVector® recommends monthly screening for mycoplasma contamination and the use of integrated mycoplasma prevention kits for maintenance.

Note: BL-31 cells should be handled under Biosafety Level 2 (BSL-2) protocols. For consistent signaling and metabolic research, BioVector® advises the use of its pre-screened FBS batches and standardized high-glucose media formulations.

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

电话:400-800-2947

工作QQ/微信同号:1843439339

网址

http://www.biovector.net